It turns out that the anti-obesity space isn't growing as fast as Eli Lilly or analysts anticipated, resulting in ...

Mounjaro: Also contains tirzepatide and shares the same mechanism of action as Zepbound. It is branded for the treatment of Type 2 diabetes but is essentially the same compound as Zepbound.

Zepbound is a dual-activating medication that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) mechanisms to tackle the root causes of obesity.

Zepbound: Recently FDA-approved in November 2023, it offers another option for patients seeking medical support for weight loss. Both medications have demonstrated excellent results in clinical ...

Eli Lilly’s expectations for sales in the fourth quarter of last year missed forecasts, driven by lower-than-expected sales of its diabetes and obesity drugs Mounjaro and Zepbound. This is ...

Medicare drug plans can now cover Eli Lilly & Co.’s obesity drug Zepbound as a treatment for obstructive sleep apnea, news that’s expected to prove a big boost for the drug company.

Once again, the drugmaker reported sales of its blockbuster GLP-1 medicines Zepbound and Mounjaro that missed Wall Street estimates. It was the second consecutive miss for the two closely watched ...

Is that the best course of action? Let's find out ... which includes drugs like Zepbound and Mounjaro, didn't grow as fast as it anticipated in the fourth quarter. Besides the fact that the ...